Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

Completed · Phase 1

Conditions studied: Glaucoma, Ocular Hypertension

In brief

This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.

Key facts

Study ID

NCT00515424

Run by

Novartis

People needed

90

Starts

2007-07-01

Last updated by the study team

2007-12-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females, ≥18 years of age, with primary open angle glaucoma and ocular hypertension
• Females must be post-menopausal or surgically sterile

You may not qualify if…

• Other types of glaucoma
• Eye pressure lowering surgeries
• A history of or current eye conditions or medical problems that would prohibit the use of an investigational drug
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Study site — Artesia, California, United States
• Study site — Rochester, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Durham, North Carolina, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.